Archive for the ‘Amgen Inc. AMGN’ Category

Beacon Equity Research Featured Company: Amgen Inc. (AMGN)

Tuesday, February 24th, 2009

Amgen Inc. is a global biotechnology company engaged in the discovery, development, manufacture and commercialization of human therapeutics based on advances in cellular and molecular biology. The company has research programs in metabolic disorders and osteoporosis, inflammation, oncology, neuroscience and hematology.

Amgen is regarded to be the largest independent biotechnology company in the U.S. The company’s main products include: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), which stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis stimulating agents (ESAs); Neulasta (pegflgrastim) and NEUPOGEN (Filgrastim), which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL (etanercept) that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis.

The company’s research facilities are located in California, Massachusetts, Washington, Canada and Germany. In addition, Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington and Puerto Rico. The company markets its products in the United States, Europe, Canada and Australia. The Company was founded in 1980 and is based in Thousand Oaks, California.

Let us hear your thoughts: Amgen Inc. Message Board

Intellectual Property takes Center Stage as Medistem (MDSM) Scientist Speaks to Regenerative Medicine Group

Friday, March 2nd, 2007

Medistem Laboratories, Inc. is an emerging Industy Leader in the development of Stem Cell therapies. Recently, Thomas Ichim, its Chief of Scientific Development, was invited to speak before the Regenerative Medicine Organization Conference. The topic of his address, was “Intellectual Property in Biotechnology”.

For example in the area of cardio valvular dysfunction, Medistem has a patent pending application for the non-surgical regeneration of valve structures involving stem cells, and its use in certain patient situations.

Medistem clearly understands that Intellectual Property remains a cornerstone pillar in the Biotech field.  The proper positioning of patents, in offensive and defensive postures, can result in attractive revenue streams from licensing royalities, for emerging firms such as Medistem.

Let us hear your thoughts below: